Fosun Pharma's Henlius Biotech merger fails

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SSE: 600196) announced that the proposed merger and privatization of its subsidiary, Shanghai Henlius Biotech, Inc., has failed. Independent H-share holders of Henlius voted against the proposal at a class meeting on January 22, 2025, preventing the deal from meeting the required approval threshold. Fosun Pharma, through its subsidiaries, currently holds 59.56% of Henlius. Although the merger will not proceed, Fosun affirmed its commitment to Henlius as a key antibody technology platform within the group. The company will continue to support Henlius’s growth and global expansion.